Tolerable treatment of glioblastoma with redox-cycling ‘mitocans': a comparative study in vivo
Open Access
- 15 August 2023
- journal article
- research article
- Published by Taylor & Francis in Redox Report
- Vol. 28 (1) , 2220531
Abstract
Objectives: The present study describes a pharmacological strategy for the treatment of glioblastoma by redoxcycling 'mitocans' such as quinone/ascorbate combination drugs, based on their tumor-selective redox-modulating effects and tolerance to normal cells and tissues.Methods: Experiments were performed on glioblastoma mice (orthotopic model) treated with coenzyme Q0/ascorbate (Q0/A). The drug was injected intracranially in a single dose. The following parameters were analyzed in vivo using MRI orex vivo using conventional assays: tumor growth, survival, cerebral and tumor perfusion, tumor cell density, tissue redox-state, and expression of tumor-associated NADH oxidase (tNOX).Results: Q0/A markedly suppressed tumor growth and significantly increased survival of glioblastoma mice. This was accompanied by increased oxidative stress in the tumor but not in non-cancerous tissues, increased tumor blood flow, and downregulation of tNOX. The redox-modulating and anticancer effects of Q0/A were more pronounced than those of menadione/ascorbate (M/A) obtained in our previous study. No adverse drug-related side-effects were observed in glioblastoma mice treated with Q0/A.Discussion: Q0/A differentiated cancer cells and tissues, particularly glioblastoma, from normal ones by redox targeting, causing a severe oxidative stress in the tumor but not in non-cancerous tissues. Q0/A had a pronounced anticancer activity and could be considered safe for the organism within certain concentration limits. The results suggest that the rate of tumor resorption and metabolism of toxic residues must be controlled and maintained within tolerable limits to achieve longer survival, especially at intracranial drug administration.Keywords
Funding Information
- IC-MedTech Corp
- Japanese Agency for Promotion of Science
- National Recovery and Resilience Plan of the Republic of Bulgaria (SUMMIT BG-RRP-2.004-0008-C01)
- Project for promoting public utilization of advanced research infrastructure
- JST/MEXT
This publication has 48 references indexed in Scilit:
- Update on a tumor-associated NADH oxidase in gastric cancer cell growthWorld Journal of Gastroenterology, 2016
- Evaluating the cytotoxic effects of novel quinone compounds.2014
- Coenzyme Q10 as a therapy for mitochondrial diseaseThe International Journal of Biochemistry & Cell Biology, 2014
- Temozolomide and unusual indications: Review of literatureCancer Treatment Reviews, 2013
- Ubiad1 Is an Antioxidant Enzyme that Regulates eNOS Activity by CoQ10 SynthesisCell, 2013
- Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzymeNature, 2010
- Molecular Cloning and Characterization of a Candidate Human Growth-Related and Time-Keeping Constitutive Cell Surface Hydroquinone (NADH) OxidaseBiochemistry, 2008
- A 12 Week, Open Label, Phase I/IIa Study Using Apatone® for the Treatment of Prostate Cancer Patients Who Have Failed Standard TherapyInternational Journal of Medical Sciences, 2008
- Inhibitory effect of coenzyme Q1 on eukaryotic DNA polymerase γ and DNA topoisomerase II activities on the growth of a human cancer cell lineCancer Science, 2006
- Ultrastructural Aspects of Autoschizis: A New Cancer Cell Death Induced by the Synergistic Action of Ascorbate/Menadione on Human Bladder Carcinoma CellsUltrastructural Pathology, 2001